Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) has been assigned a consensus recommendation of “Buy” from the eleven research firms that are covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and nine have assigned a buy rating to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $52.63.

Several research analysts have issued reports on BHVN shares. Cantor Fitzgerald set a $57.00 price objective on Biohaven Pharmaceutical and gave the stock a “buy” rating in a report on Wednesday, September 12th. ValuEngine raised Biohaven Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Wednesday, October 3rd. Piper Jaffray Companies set a $65.00 price target on Biohaven Pharmaceutical and gave the company a “buy” rating in a research note on Wednesday, September 12th. Zacks Investment Research downgraded Biohaven Pharmaceutical from a “hold” rating to a “sell” rating in a research note on Tuesday, October 16th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $48.00 price target on shares of Biohaven Pharmaceutical in a research note on Friday, August 17th.

NYSE:BHVN opened at $42.90 on Tuesday. Biohaven Pharmaceutical has a 52-week low of $16.50 and a 52-week high of $44.28. The firm has a market cap of $1.66 billion, a price-to-earnings ratio of -8.58 and a beta of 1.16.

Biohaven Pharmaceutical (NYSE:BHVN) last posted its quarterly earnings data on Wednesday, November 14th. The company reported ($1.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.05) by ($0.48). Equities analysts expect that Biohaven Pharmaceutical will post -6.07 earnings per share for the current year.

Hedge funds have recently bought and sold shares of the company. Tower Research Capital LLC TRC increased its position in shares of Biohaven Pharmaceutical by 602.4% in the 3rd quarter. Tower Research Capital LLC TRC now owns 5,057 shares of the company’s stock valued at $190,000 after buying an additional 4,337 shares in the last quarter. SG Americas Securities LLC bought a new stake in shares of Biohaven Pharmaceutical in the 2nd quarter valued at $191,000. Quantitative Systematic Strategies LLC bought a new stake in shares of Biohaven Pharmaceutical in the 2nd quarter valued at $205,000. Shell Asset Management Co. bought a new stake in shares of Biohaven Pharmaceutical in the 3rd quarter valued at $205,000. Finally, AQR Capital Management LLC bought a new stake in shares of Biohaven Pharmaceutical in the 3rd quarter valued at $218,000. 77.63% of the stock is currently owned by institutional investors.

Biohaven Pharmaceutical Company Profile

Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops product candidates to treat neurological diseases, including rare disorders. Its lead product candidate is rimegepant, which is in Phase III clinical trials for the acute treatment of migraine. The company also develops trigriluzole, which is in a Phase II/III clinical trial used for the treatment of ataxias with an initial focus on spinocerebellar ataxia; and Phase II/III clinical trial for the treatment of obsessive compulsive disorders, as well as for the treatment of Alzheimer's diseases.

Read More: Is the Dow Jones Industrial Average (DJIA) still relevant?

Analyst Recommendations for Biohaven Pharmaceutical (NYSE:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.